Page 5 - David Persing News Today : Breaking News, Live Updates & Top Stories | Vimarsana

/PRNewswire/ -- Cepheid actively monitors COVID-19 virus mutations and is well prepared to support detection of the "Omicron" B.1.1.529 variant with its...

/PRNewswire/ -- Cepheid actively monitors COVID-19 virus mutations and is well prepared to support detection of the "Omicron" B.1.1.529 variant with its...

Cepheid Gets Health Canada License For Four-in-one Rapid Molecular Diagnostic Test WASHINGTON (dpa-AFX) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and RSV infections from a single patient sample. The test is now available in Canada and can be used in laboratories and at the point of care. Cepheid noted that the four-in-one test is designed for use on any of the company's al...

(Nasdaq) It didn’t look good for IPOs when the pandemic took hold. COVID-19, social distancing and general uncertainty upended the public markets, leading Renaissance Capital to predict IPOs to “grind to a virtual halt” in the spring. But experts predicted that biotech IPOs would be the silver lining in an otherwise dismal year. What they didn’t predict was just how successful the sector would be. “I was the most bullish, aggressive person ever with my prediction and I was off by almost 50%. I had to revise it twice,” said Jordan Saxe, the head of healthcare listings at N...